Feb 15, 2018   SOURCE: PR NewsWire

Global Hepatitis C Disease Forecast and Market Analysis 2018-2035: Pricing is the Key Differentiator for Drugs in This Market

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Hepatitis C Disease Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Market Snapshot

    --  Falling disease prevalence and anticipated price decreases as
        competition intensifies will drive a net decline in market value.
    --  Harvoni remains the dominant option for GT-1/4 patients, but has ceded
        share to cheaper rivals as competition intensifies.
    --  Cases are expected to decline, driven by complexities in high-risk
        populations, demographics, and treatment developments.
    --  Mavyret's approval at a substantial discount to Epclusa paves the way
        for a further decline in Gilead's HCV revenues.
    --  Lack of unmet need and declining market value prompts Johnson & Johnson
        and Merck & Co to discontinue pipeline regimens.
    --  Pricing is the key differentiator for drugs in this market.

Key Topics Covered:

Forecast: Hepatitis C

    --  Executive Summary
    --  Market Dynamics
    --  Forecast And Future Trends
    --  Market Definition And Methodology
    --  Primary Research Methodology
    --  Bibliography
    --  Product Profile: Daklinza
    --  Product Profile: Epclusa
    --  Product Profile: Harvoni
    --  Product Profile: Mavyret
    --  Product Profile: Sovaldi
    --  Product Profile: Viekira Pak Franchise
    --  Product Profile: Vosevi
    --  Product Profile: Ximency
    --  Product Profile: Zepatier

Treatment: Hepatitis C

    --  Executive Summary
    --  Primary Research Methodology
    --  Disease Definition And Diagnosis
    --  Patient Segmentation
    --  Current Treatment Options
    --  Prescribing Trends
    --  Unmet Needs In Hepatitis C

Epidemiology: Hepatitis C In The Us, Japan, And 5EU

    --  Executive Summary
    --  Disease Overview
    --  Sources And Methodology
    --  Forecast
    --  Epidemiologist Insight
    --  Strengths And Limitations
    --  Bibliography

Marketed Drugs: Hepatitis C

    --  Executive Summary
    --  Product Overview
    --  Product Profile: Daklinza
    --  Product Profile: Epclusa
    --  Product Profile: Harvoni
    --  Product Profile: Mavyret
    --  Product Profile: Sovaldi
    --  Product Profile: Viekira Pak Franchise
    --  Product Profile: Vosevi
    --  Product Profile: Ximency
    --  Product Profile: Zepatier

Hepatitis C Pricing, Reimbursement, And Access

    --  Executive Summary
    --  Regulatory Labels
    --  Payer Archetypes
    --  Access To Recently Launched And Pipeline Products
    --  Evidentiary Requirements And Future Pipeline Potential
    --  Us Pricing
    --  Us Reimbursement
    --  Japan
    --  Pricing In The Five Major Eu Markets
    --  France
    --  Germany
    --  Italy
    --  Spain
    --  Uk
    --  Methodology

Pipeline: Hepatitis C

    --  Executive Summary
    --  Pipeline Trends

For more information about this report visit https://www.researchandmarkets.com/research/sz2jbf/global_hepatitis?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-hepatitis-c-disease-forecast-and-market-analysis-2018-2035-pricing-is-the-key-differentiator-for-drugs-in-this-market-300599398.html

SOURCE Research and Markets